Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: Association with Th2 cytokines not anergy

Transplantation

Volumn 67, Issue 4, 1999, Pages 605-613

  Plain, Karren M ^a   Chen, Juchuan ^a   Merten, Steven ^a   He, Xiao Y ^a   Hall, Bruce M ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; GRANZYME A; GRANZYME B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY G4 18; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE CELL; LYMPHOCYTE DEPLETION; MIXED LEUKOCYTE CULTURE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

EID: 0033608422     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199902270-00020     Document Type: Article

References (68)

1. Waldmann H, Qin S, Cobbold SP. Monoclonal antibodies for the therapeutic induction of tolerance. Immunology Ser 1993; 59: 85.
2. Norman DJ, Kahana L, Stuart FJ, al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
3. Ortho M. Transplant Study Group. A randomised clinical trial of OKT3 in cadaver kidney transplant recipients. Transplantation 1985; 45: 546.
4. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
5. Ortho M. Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody therapy for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
6. Nicolls MR, Aversa GG, Pearce NW, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459.
7. Woodley SL, Gurley KE, Hoffmann SL, et al. Induction of tolerance to heart allografts in rats using posttransplant total lymphoid irradiation and anti-T cell antibodies. Transplantation 1993; 56: 1443.
8. Mottram PL, Han W-R, Murray-Segal LJ, Mandel TE, Pietersz GA, McKenzie IFC. Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice. Transplantation 1997; 64: 684.
9. Mackie JD, Pankewycz OG, Boston MG, Kelley VE, Strom TB. Dose related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibodies. Transplantation 1990; 49: 1150.
10. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab́)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117.
11. Alegre ML, Tso JY, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fcg receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155: 1544.
12. Vossen AC, Knulst AC, Tibbe GJ, et al. Suppression of skin allograft rejection in mice by anti-CD3 monoclonal antibodies without cytokine-related side-effects. Transplantation 1994; 58: 257.
13. Chatenoud L, Primo J, Bach J-F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 2947.
14. Abramowicz D, Schandene L, Goldman M, et al. Release of tumour necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
15. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to anti-T cells monoclonal antibody OKT3 in relation to serum levels of TNF and IFN-gamma. N Engl J Med 1989; 320: 1420.
16. Bergese SD, Pelletier RP, Ohye RG, Vallera DA, Orosz CG. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Transplantation 1994; 57: 711.
17. Goldstein G, Schindler J, Sheahan M, Barnes L, Tsai H. Orthoclone OKT3 treatment of acute renal allograft rejection. Transplant Proc 1985; 17: 129.
18. Kan EAR, Wright SD, Welte K, Wang CY. Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell. Immunol 1986; 98: 181.
19. Tax WJ, Tamboer WP, Jacobs CW, Frenken LA, Koene RA. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31). Transplantation 1997; 63: 106.
20. Krutmann J, Kirnbauer R, Kock A, et al. Cross-linking of Fc receptors on monocytes triggers 11-6 production. Role in anti-CD3 induced T cell activation. J Immunol 1990; 145: 1337.
21. Debets JM, Van de Winkel JG, Cueppens IE, Dieteren M, Buurman WA. Cross-linking of both FcgRI and FcgRII induces secretion of tumour necrosis factor by human monocytes, requiring high affinity Fc-FcgR interactions: functional activation of FcgRII by protease or neuraminidase. J Immunol 1990; 144: 1304.
22. Goumy L, Ferran C, Merite S, Bach JF, Chatenoud L. In vivo anti-CD3-driven cell activation. Cellular source of induced tumor necrosis factor, interleukin-1 beta, and interleukin-6. Transplantation 1996; 61: 83.
23. Parlevliet KJ, ten Berge IJ, Yong SL, Surachno J, Wilmink JM, Schellekens PT. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93: 2519.
24. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144: 16.
25. Williams ME, Lichtman AH, Abbas AK. Anti-CD3 antibody induces unresponsiveness to IL-2 to Th 1 clones but not Th2 clones. J Immunol 1990; 144: 208.
26. Anasetti C, Tan P, Hansen JA, Martin PJ. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J Exp Med 1990; 172: 1691.
27. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994; 264: 1587.
28. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185: 1413.
29. Smith JA, Bluestone JA. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 1997; 9: 648.
30. Hughes C, Wolos JA, Giannini EH, Hirsch R. Induction of T cell unresponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody. J Immunol 1994; 153: 3319.
31. Parlevliet KJ, Chamuleau ME, Yong SL, Raasveld MH, ten BIJ, Schellekens PT. Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro. Clin & Exp Immunol 1995; 99: 155.
32. Thistlethwaite JR, Jr., Cosimi AB, Delmonico FL, et al. Evolving use of OKT3 monoclonal antibody for treatment of renal allograft rejection. Transplantation 1984; 38: 695.
33. Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989; 142: 737.
34. + T cells in vitro. Int Immunol 1997; 9: 935.
35. Wissing M, Alegre ML, Abramowicz D, et al. Emergence of Th2-like cells after anti-CD3 monoclonal antibody administration in mice. Transplant Proc 1995; 27: 378.
36. Ben-Amor A, Leite-De-Moraes M, Lepault F, et al. Role of interleukin-2 receptors in the suppressive effect of spleen cells from anti-CD3-treated mice. Eur Cytokine Netw 1995; 6: 221.
37. Sawchuk SS, Gates R, Hirsch R. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab′)2) anti-CD3 monoclonal antibody. Transplantation 1995; 60: 1331.
38. Andris F, Van MM, De MF, Baus E, Urbain J, Leo O. Induction of T cell unresponsiveness by anti-CD3 antibodies occurs independently of co-stimulatory functions. Eur J Immunol 1996; 26: 1187.
39. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
40. Mottram PL, Han WR, Purcell LJ, McKenzie IFC, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59: 559.
41. + T cell subsets in low- and high-responder rat strains. J Immunol 1989; 143: 2828.
42. DeFoma FJ, MacDonald AB. Analysis of antigens by immunodiffusion and immunoelectrophoresis. In: DeFoma FJ, MacDonald AB, eds. Experimental immunology: a guidebook. New York: Macmillan, 1987: 49.
43. Hall BM, deSaxe I, Dorsch SE. The cellular basis of allograft rejection in vivo. III. Restoration of first-set rejection of heart grafts by T helper cells in irradiated rats. Transplantation 1983; 36: 700.
44. Plain KM, Fava L, Spinelli A, et al. Induction of tolerance with non depleting anti-CD4 monoclonal antibody is associated with down regulation of Th2 cytokines. Transplantation 1997; 64: 1559.
45. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
46. Penny MJ, Boyd RA, Hall BM. Role of T cells in the mediation of Heymann nephritis. ii. Identification of Th1 and cytotoxic cells in glomeruli. Kidney Int 1997; 51: 1059.
47. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403.
48. Alegre ML, Peterson LJ, Xu D, et al. A non-activating humanized anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537.
49. + T cells. Transplantation 1996; 61: 798.
50. Hall BM, Gurley KE, Dorsch SE. The possible role of cytotoxic T cells in the mediation of first-set allograft rejection. Transplantation 1985; 40: 336.
51. McConnell MV, Hall BM. Comparison of CD4 and CD8 T cell reactivity in high-responder and low-responder strain combinations in the rat. Transplant Proc 1989; 21: 3294.
52. Hall BM. Cells mediating allograft rejection [published erratum appears in Transplantation 1991; 52(5): 936]. Transplantation 1991; 51: 1141.
53. Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med 1985; 162: 1683.
54. Armstrong HE, Bolton EM, McMillan I, Spencer SC, Bradley JA. Prolonged survival of actively enhanced rat renal allografts despite accelerated cellular infiltration and rapid induction of both class I and class II MHC antigens. J Exp Med 1987; 165: 891.
55. Dallman MJ, Wood KJ, Morris PJ. Specific cytotoxic T cells are found in nonrejected kidneys of blood transfused rats. J Exp Med 1987; 165: 566.
56. + T cells. J Immunol 1989; 143: 499.
57. Dallman MJ, Shiho O, Page TH, Wood KJ, Morris PJ. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med 1991; 173: 79.
58. Abramowicz D, Durez P, Gerard C, al. Neonatal induction of transplantation tolerance in mice is associated with in vivo expression of IL-4 and IL-10 mRNAs. Transplant Proc 1990; 25: 312.
59. Chen N, Gao Q, Field EH. Expansion of memory TH2 cells over TH1 cells in neonatal primed mice. Transplantation 1995; 60: 1187.
60. Chen N, Gao Q, Field EH. Prevention of TH1 responses is critical for tolerance. Transplantation 1996; 61: 1076.
61. Zeng D, Ready A, Huie K, et al. Mechanisms of tolerance to rat heart allografts using posttransplant TLI. Transplantation 1996; 62: 510.
62. Siegling A, Lehmann M, Riedel H, et al. A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation 1994; 57: 464.
63. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
64. Takeuchi T, Ueki T, Sunaga S, et al. Murine interleukin 4 transgenic heart allograft survival prolonged with down-regulation of TH1 cytokine mRNA in grafts. Transplantation 1997; 64: 152.
65. He XY, Chen J, Verma N, Plain K, Tran G, Hall BM. Treatment with IL-4 prolongs allogeneic neonatal heart graft survival by inducing Th2 responses. Transplantation 1998; 65.
66. Schurmans S, Heusser CH, Qin HY, Merino J, Brighouse G, Lambert PH. In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome. J Immunol 1990; 145: 2465.
67. Donckier V, Wissing M, Abramowicz D, et al. Early neutralization of IL-4 but not of IL-10 abrogates neonatal induction of transplantation tolerance in mice. Transplant Proc 1995; 27: 186.
68. Field EH, Rouse TM, Gao Q, Chang B. Associations between enhanced Th1/Th2 cytokine profile and donor T cell chimerism following total lymphoid irradiation. Hum Immunol 1997; 52: 144.